Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge
Viruses · 2023
DOI: 10.3390/v15020356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Ryan S Noyce und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology & Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2R3, Canada. Hauptthemen laut MEDLINE: Orthopoxvirus, Mpox, Monkeypox, Smallpox, Poxviridae Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tonix Pharmaceuticals.
Abstract (Originalsprache)
The ongoing global Monkeypox outbreak that started in the spring of 2022 has reinforced the importance of protecting the population using live virus vaccines based on the vaccinia virus (VACV). Smallpox also remains a biothreat and although some U.S. military personnel are immunized with VACV, safety concerns limit its use in other vulnerable groups. Consequently, there is a need for an effective and safer, single dose, live replicating vaccine against both viruses. One potential approach is to use the horsepox virus (HPXV) as a vaccine. Contemporary VACV shares a common ancestor with HPXV, which from the time of Edward Jenner and through the 19th century, was extensively used to vaccinate against smallpox. However, it is unknown if early HPXV-based vaccines exhibited different safety and efficacy profiles compared to modern VACV. A deeper understanding of HPXV as a vaccine platform may allow the construction of safer and more effective vaccines against the poxvirus family. In a proof-of-concept study, we vaccinated cynomolgus macaques with TNX-801, a recombinant chimeric horsepox virus (rcHPXV), and showed that the vaccine elicited protective immune responses against a lethal challenge with monkeypox virus (MPXV), strain Zaire. The vaccine was well tolerated and protected animals from the development of lesions and severe disease. These encouraging data support the further development of TNX-801.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology & Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2R3, Canada.
- Southern Research, Birmingham, AL 35205, USA.
- Tonix Pharmaceuticals, Dartmouth, MA 02748, USA.
- LINQ Pharma Consulting Inc., Aldie, VA 20105, USA.
- Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
ORCID-Profile: Ryan S Noyce, José Esparza, David H Evans, Seth Lederman
Förderung
- Tonix Pharmaceuticals
Zitieren
APA
Noyce, R. S., Westfall, L. W., Fogarty, S., Gilbert, K., Mpanju, O., Stillwell, H., Esparza, J., Daugherty, B., Koide, F., Evans, D. H., & Lederman, S. (2023). Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge. Viruses. https://doi.org/10.3390/v15020356
Vancouver
Noyce RS, Westfall LW, Fogarty S, Gilbert K, Mpanju O, Stillwell H, et al. Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge. Viruses. 2023. doi:10.3390/v15020356
BibTeX
@article{Noyce2023,
author = {Noyce, Ryan S and Westfall, Landon W and Fogarty, Siobhan and Gilbert, Karen and Mpanju, Onesmo and Stillwell, Helen and Esparza, José and Daugherty, Bruce and Koide, Fusataka and Evans, David H and Lederman, Seth},
title = {Single Dose of Recombinant Chimeric Horsepox Virus (TNX-801) Vaccination Protects Macaques from Lethal Monkeypox Challenge},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15020356}
}
EUVIMED